Decentralized NGS in Oncology Trials Webinar

Overcoming oncology trial challenges with decentralized and rapid NGS

In this webinar, the speakers discuss the transformative role of decentralized NGS in streamlining trial operations. By decentralized NGS testing, clinical trials can significantly reduce reliance on central laboratories – which minimizes delays in sample transportation and processing – and enable faster identification of eligible patients.

This webinar also covers the critical importance of timely genomic profiling in clinical trials. As the identification of relevant mutations can directly impact treatment decisions, the rapid turnaround time of advanced NGS platform enables investigators with the crucial information for timely and informed decisions.

• Observe an overview of the key challenges and complexities with oncology biomarker driven clinical trials
• Discover key considerations when managing oncology biomarker driven trials
• Gain understanding of rapid and decentralized NGS technologies in order to better identify eligible patients in order to minimize clinical trial delays

Speakers

Speakers

Jane Li
Senior director, pharma and CRO
Life sciences solutions, Thermo Fisher Scientific
Jane.Li@thermofisher.com

Binh Nguyen
Vice president, medical science and strategy
PPD clinical research business, Thermo Fisher Scientific
Binh.Nguyen@ppd.com

Chris Morris
Senior director, consulting, innovation and strategy
Patient first digital solutions
PPD clinical research business, Thermo Fisher Scientific
Christopher.Morris@ppd.com

Jacinda Snow
Senior director, project management
Hematology and oncology
PPD clinical research business, Thermo Fisher Scientific
Jacinda.Snow@ppd.com